DJS Antibodies was founded upon a vision of creating the next generation of antibody therapeutics. We developed HEPTAD, a revolutionary platform for antibody discovery, and now use this to create novel therapeutics that will have a meaningful impact on the lives of patients.
In 2022, DJS Antibodies was acquired by AbbVie. Together, we are working to advance our unique pipeline and deliver new medicines to patients.
We believe that creating a culture of scientific excellence is the best way to make a meaningful difference to patients’ lives. There are brilliant people behind every medical breakthrough and our team is passionate about delivering scientific innovation to make tomorrow’s breakthroughs a reality.
If you're looking to be surrounded by fantastic people and join an exciting team working on the cutting edge of drug discovery, get in touch!
